Dec 1, 2022 | 2022, Press Releases, Scientific
The management team to hold a Webinar on Dec 1, 2022, at 10:00 ET / 15:00 GMT / 16:00 CET (Please find the link for the webinar here). Corporate_Update_Dec 1Nov 18, 2022 | 2022, Press Releases, Scientific
The study describes the development of a novel anti-PD-1 antibody that shows potent blockade of PD-1 with a different recognition mechanism compared to anti-PD-1 antibodies that have recently reached the market. For more detailsNov 11, 2022 | 2022, Press Releases, Scientific
The study describes the discovery of GCPIII as the protein responsible for the accumulation of conventional PSMA targeting agents in healthy organs. More detailsNov 7, 2022 | 2022, Press Releases, Scientific
Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands isolated from DNA-Encoded Chemical Libraries. The novel OncoFAP ligands show a prolonged residence time in Fibroblast Activation Protein (FAP) positive tumors. The...Oct 19, 2022 | 2022, Press Releases, Scientific
The study shows excellent tumor uptake of the novel OncoFAP-MMAE Small Molecule-Drug Conjugates (SMDCs) with high and selective release of the cytotoxic MMAE payload at the tumor site. OncoFAP-based pro-drugs are currently being developed for the imaging and therapy...Sep 15, 2022 | 2022, Press Releases, Scientific
The study shows selective tumor uptake of IL12-7NP2 and potent antitumor activity as single agent and in combination with immune checkpoint inhibitors. The product is well tolerated when administered to non-human primates. More details
Recent Comments